References
Breckenridge A, Dollery C, Rawlins M, Walport M (2006) The future of clinical pharmacology in the UK. Lancet 367(9516):1051
Maxwell SR, Webb DJ (2006) Clinical pharmacology—too young to die? Lancet 367(9513):799–800
Aronson JK (2010) Clinical pharmacology and therapeutics in the UK – a great instauration. Br J Clin Pharmacol 69(2):111–117
Walport M, Foulkes I, Weissberg P, Morgan D, Nebhrajani S (2012) Medical research: no catch to UK charity funding. Nature 482(7385):308
Zineh I, Woodcock J (2013) Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin Pharmacol Ther 93(6):515–525
Gaddum JH (1954) Clinical pharmacology. Proc R Soc Med 47(3):195–204
Agoram BM (2008) Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 67(2):153–160
Mavilio F (2017) Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry. Gene Ther 24(9):590–592
Vezmar Kovačević S, Simišić M, Stojkov Rudinski S, Ćulafić M, Vučićević K, Prostran M, Miljković B (2014) Potentially inappropriate prescribing in older primary care patients. PLoS ONE 9(4):e95536
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT (2007) Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 370:173–184
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):
Martin JH, Henry D, Gray J et al (2016) Achieving the World Health Organization’s vision for clinical pharmacology. Br J Clin Pharmacol 81(2):223–227
Thomson S, Figueras J, Evetovits T et al (2014) Economic crisis, health systems and health in Europe: impact and implications for policy. WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies. http://www.euro.who.int/en/about-us/partners/observatory/publications/studies/economic-crisis,-health-systems-and-health-in-europe.-impact-and-implications-for-policy-2015. Accessed 15 april 2017
Allegaert K, Langhendries JP, van den Anker JN (2013) Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 172(4):429–435
Kearns GL (2009) The pursuit of pediatric clinical pharmacology: perspectives from a current journey. J Pediatr Pharmacol Ther 14(1):10–16
Chen R, Snyder M (2012) Systems biology: personalized medicine for the future? Curr Opin Pharmacol 12(5):623–628
Roger SD, Goldsmith D (2008) Biosimilars: it’s not as simple as cost alone. J Clin Pharm Ther 33:459–464
Hawcutt DB, Russell NJ, Maqsood H et al (2016) Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. Br J Clin Pharmacol 82(6):1601–1612
Paul IM (2010) Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr 57:163–183
Birkett D, Brøsen K, Cascorbi I et al (2010) Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 107(1):531–559
Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance. Available at: https://publications.europa.eu/en/publication-detail/-/publication/c1ad51e2-2e32-11e2-ad46-01aa75ed71a1. Accessed 20 April 2017
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 ("Clinical Trials Directive"). Available at: https://ec.europa.eu/health/human-use/clinical-trials/directive_en. Accessed 20 April 2017
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Available at: http://eur-lex.europa.eu Accessed 20 April 2017
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at: http://eur-lex.europa.eu. Accessed 20 April 2017
Clinical Pharmacology in Health Care, Teaching and Research. Geneva: Council for the International Organizations of Medical Sciences; (2012). Available at: http://apps.who.int/medicinedocs/documents/s19916en/s19916en.pdf. Accessed 12 April 2017
Acknowledgements
The authors would like to acknowledge Professor David Webb and Doctor Lee Page of British Pharmacological Society, Professor Alexander Jetter of Klinik für Klinische Pharmakologie und Toxikologie, Zurich. The authors would also like to acknoweledge Omar Alexander for his contributions in the linguistic revising.
Contributors
DG and VAC were responsible for the study concept and design under the supervision of FS. The literature search, abstract screening, and data extraction were undertaken by DG with further confirmation by AC, GS and VAC. DG wrote the manuscript that was reviewed by AC. All the authors have read and approved the final manuscript submitted.
Funding
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Grisafi, D., Ceschi, A., Sava, G. et al. Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review. Eur J Clin Pharmacol 74, 1663–1670 (2018). https://doi.org/10.1007/s00228-018-2511-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2511-8